Phreesia, Inc. $PHR Position Lessened by Cambiar Investors LLC

Cambiar Investors LLC lowered its stake in shares of Phreesia, Inc. (NYSE:PHR) by 35.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 240,793 shares of the company’s stock after selling 134,272 shares during the quarter. Cambiar Investors LLC’s holdings in Phreesia were worth $5,663,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PHR. Asset Management One Co. Ltd. bought a new stake in Phreesia in the third quarter valued at $45,000. Farther Finance Advisors LLC increased its holdings in shares of Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company’s stock worth $86,000 after acquiring an additional 3,000 shares during the period. State of Alaska Department of Revenue bought a new stake in Phreesia in the 3rd quarter valued at about $83,000. Tower Research Capital LLC TRC lifted its position in Phreesia by 332.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company’s stock valued at $160,000 after purchasing an additional 4,313 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new position in Phreesia during the 2nd quarter valued at about $246,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on PHR. Canaccord Genuity Group dropped their price target on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, December 9th. Robert W. Baird lowered their target price on Phreesia from $31.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 10th. Mizuho reduced their price target on Phreesia from $36.00 to $28.00 and set an “outperform” rating for the company in a research report on Wednesday, December 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Phreesia in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. cut their price objective on shares of Phreesia from $32.00 to $29.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 9th. Seventeen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Phreesia presently has an average rating of “Moderate Buy” and an average target price of $29.76.

Phreesia Stock Down 3.5%

Shares of PHR stock opened at $15.16 on Wednesday. Phreesia, Inc. has a 1 year low of $14.65 and a 1 year high of $32.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The business’s fifty day moving average is $17.50 and its 200-day moving average is $22.64. The stock has a market cap of $914.12 million, a PE ratio of -151.60 and a beta of 0.61.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.11. The business had revenue of $120.33 million during the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company’s revenue was up 12.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. Equities analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Activity at Phreesia

In related news, CFO Balaji Gandhi sold 8,009 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $136,233.09. Following the completion of the sale, the chief financial officer directly owned 156,231 shares of the company’s stock, valued at $2,657,489.31. This represents a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Linetsky sold 6,106 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $103,863.06. Following the sale, the insider owned 231,723 shares of the company’s stock, valued at $3,941,608.23. The trade was a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 60,766 shares of company stock worth $1,013,817. Company insiders own 5.50% of the company’s stock.

Phreesia Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.